4.6 Article

Molecular features of early onset adult myelodysplastic syndrome

期刊

HAEMATOLOGICA
卷 102, 期 6, 页码 1028-1034

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2016.159772

关键词

-

资金

  1. NIH/NHLBI [R01 HL118281, R01 HL123904, R01 HL128425]
  2. Edward P. Evans Foundation
  3. American Cancer Society [123436-RSG-12-159-01-DMC]

向作者/读者索取更多资源

Myelodysplastic syndromes are typically diseases of older adults. Patients in whom the onset is early may have distinct molecular and clinical features or reflect a demographic continuum. The identification of differences between early onset patients and those diagnosed at a traditional age has the potential to advance understanding of the pathogenesis of myelodysplasia and may lead to formation of distinct morphological subcategories. We studied a cohort of 634 patients with various subcategories of myelodysplastic syndrome and secondary acute myeloid leukemia, stratifying them based on age at presentation and clinical parameters. We then characterized molecular abnormalities detected by next-generation deep sequencing of 60 genes that are commonly mutated in myeloid malignancies. The number of mutations increased linearly with age and on average, patients > 50 years of age had more mutations. TET2, SRSF2, and DNMT3A were more commonly mutated in patients > 50 years old compared to patients <= 50 years old. In general, patients > 50 years of age also had more mutations in spliceosomal, epigenetic modifier, and RAS gene families. Although there are age-related differences in molecular features among patients with myelodysplasia, most notably in the incidence of SRSF2 mutations, our results suggest that patients <= 50 years old belong to a disease continuum with a distinct pattern of early onset ancestral events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Sex Influences Age-Related Changes in Natural Antibodies and CD5+B-1 Cells

Sarah E. Webster, Brinda Ryali, Michael J. Clemente, Naomi L. Tsuji, Nichol E. Holodick

Summary: The protective capacity of serum IgM against pneumococcal infection is maintained in aged female mice but absent in aged male mice. Aged female mice have a more diverse and active CD5+ B-1 cell pool and natural IgM repertoire, which may have implications for sex-related susceptibility to infection and disease.

JOURNAL OF IMMUNOLOGY (2022)

Article Hematology

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero

Summary: The combination of enasidenib with azacitidine showed a 74% overall response rate in newly diagnosed mIDH2 MDS patients, while enasidenib monotherapy achieved a 35% response rate in patients after HMA failure. These findings demonstrate that enasidenib is an effective treatment option for mIDH2 MDS.

BLOOD ADVANCES (2023)

Meeting Abstract Hematology

New Approaches to Chronic Idiopathic Neutropenia in the Era of Clonal Hematopoiesis

Olisaemeka Ogbue, Tariq Kewan, Waled Bahaj, Carmelo Gurnari, Valeria Visconte, Suresh Kumar Balasubramanian, Bhumika J. Patel, Alan Lichtin, Hetty E. Carraway, Jaroslaw P. Maciejewski

Meeting Abstract Hematology

Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations

Jaymeson Gordon, Christopher Haddad, Ishani Nautiyal, Yasuo Kubota, Hetty E. Carraway, Sudipto Mukherjee, Aaron T. Gerds, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Carmelo Gurnari, Valeria Visconte

Letter Hematology

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Tariq Kewan, Waled Bahaj, Arda Durmaz, Mai Aly, Olisaemeka D. Ogbue, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski

Meeting Abstract Hematology

Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial

Eric Padron, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Meagan Horton, Aaron T. Gerds, David A. Sallman, Andrew Kuykendall, David Steensma, Maria E. Balasis, Jeffrey E. Lancet, Mikkael A. Sekeres, Rami S. Komrokji

Meeting Abstract Hematology

Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome

Tariq Kewan, Waled Bahaj, Mai Aly, Arda Durmaz, Olisaemeka Ogbue, Hetty E. Carraway, Abhay Singh Singh, Suresh Kumar Balasubramanian, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski

Meeting Abstract Hematology

Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia

Fauzia Ullah, Danai Dima, Carmelo Gurnari, Suresh Kumar Balasubramanian, Olisaemeka Ogbue, Hussein Awada, Naomi Kawashima, Najiullah Omar, Swapna Thota, Hetty E. Carraway, Valeria Visconte, Jaroslaw P. Maciejewski

Meeting Abstract Hematology

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Nicholas Short, Tae Kon Kim, Rustin Lovewell, Elizabeth A. Griffiths, Hetty E. Carraway, Stephanie Zeidan, Elizabeth Knowles, Megan Nelson, Jahangheer Shaik, Chelsea Zhou, Emilia Alina Barbu, Zachary Cusumano, Subhadip Kundu, Sasan Sharee, Ron Copeland, Dallas Flies, Solomon Langermann, Han Myint, Jessica K. Altman, Farhad Ravandi

Article Hematology

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Amer M. Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Ades, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E. Carraway, Naval Daver, Maria Diez-Campelo, Theo de Witte, Amy E. DeZern, Fabio Efficace, Guillermo Garcia-Manero, Jacqueline S. Garcia, Ulrich Germing, Aristoteles Giagounidis, Elizabeth A. Griffiths, Robert P. Hasserjian, Eva Hellstrom-Lindberg, Marcelo Iastrebner, Rami Komrokji, Austin G. Kulasekararaj, Luca Malcovati, Yasushi Miyazaki, Olatoyosi Odenike, Valeria Santini, Guillermo Sanz, Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux

Summary: The initial response criteria developed by the International Working Group (IWG) in 2000 have limitations in their application to higher-risk MDS and their ability to fully capture the clinical benefits of novel investigational drugs. Therefore, an international panel of MDS experts used a modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results.
Meeting Abstract Hematology

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Julia H. Joo, Yanwen Chen, Aaron T. Gerds, Anjali Advani, Sophia R. Balderman, Hetty E. Carraway, Abhay Singh Singh, Sudipto Mukherjee

Meeting Abstract Oncology

Age-, sex-, and race-related disparities in receipt of HypomethyLating Agents (HMA) for the treatment of myelodysplastic syndrome (MDS)

Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani, Siran M. Koroukian

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).

Farhad Ravandi-Kashani, Ashwin Kishtagari, Hetty Carraway, Emily Curran, Gary Schiller, Alex Cacovean, Bhagyashree Yadav, Thomas Butler, Jeffrey Lancet

CANCER RESEARCH (2022)

Meeting Abstract Oncology

COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma

Farhad Ravandi, Hetty Carraway, Jack Khouri, Ashwin Kishtagari, Emily Curran, Gary Schiller, Bhagyashree (Kelshikar) Yadav, Steve Morris, Alex Cacovean, Sanchita Mourya, Thomas Butler, Jeffrey Lancet

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Meeting Abstract Oncology

COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).

Farhad Ravandi, Ashwin Kishtagari, Hetty E. Carraway, Gary J. Schiller, Steve Morris, Alexandru Cacovean, Bhagyashree Kelshikar Yadav, Thomas Butler, Jeffrey E. Lancet

JOURNAL OF CLINICAL ONCOLOGY (2022)

暂无数据